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Abstract Although benzophenone-3 (BP-3) has frequently
been reported to play a role in endocrine disruption, there is
insufficient data regarding the impact of BP-3 on the nervous
system, including its possible adverse effects on the develop-
ing brain. Our study demonstrated that BP-3 caused neurotox-
icity and activated apoptosis via an intrinsic pathway involv-
ing the loss of mitochondrial membrane potential and the ac-
tivation of caspases-9 and -3 and kinases p38/MAPK and
Gsk3β. These biochemical alterations were accompanied by
ROS production, increased apoptotic body formation and im-
paired cell survival, and by an upregulation of the genes in-
volved in apoptosis. The BP-3-induced effects were tissue-
specific and age-dependent with the most pronounced effects
observed in neocortical cells at 7 days in vitro. BP-3 changed
the messenger RNA (mRNA) expression levels of Erα, Erβ,
Gpr30, and Pparγ in a time-dependent manner. At 3 h of
exposure, BP-3 downregulated estrogen receptor mRNAs
but upregulated Pparγ mRNA. After prolonged exposures,
BP-3 downregulated the receptor mRNAs except for Erβ
mRNA that was upregulated. The BP-3-induced patterns of
mRNA expression measured at 6 and 24 h of exposure
reflected alterations in the protein levels of the receptors and
paralleled their immunofluorescent labeling. Erα and Pparγ
agonists diminished, but Erβ and Gpr30 agonists stimulated
the BP-3-induced apoptotic and neurotoxic effects. Receptor
antagonists caused the opposite effects, except for ICI
182,780. This is in line with a substantial reduction in the
effects of BP-3 in cells with siRNA-silenced Erβ/Gpr30 and
the maintenance of BP-3 effects in Erα- and Pparγ siRNA-
transfected cells. We showed for the first time that BP-3-
affected mRNA and protein expression levels of Erα, Erβ,
Gpr30, and Pparγ, paralleled BP-3-induced apoptosis and
neurotoxicity. Therefore, we suggest that BP-3-evoked apo-
ptosis of neuronal cells is mediated via attenuation of Erα/
Pparγ and stimulation of Erβ/Gpr30 signaling.
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Introduction
The toxicity of ultraviolet light (UV) filters used in sunscreens
and cosmetics to attenuate the negative effects of harmful UV
radiation on skin and hair has become a concern. More than
approximately 10,000 tons of UV filters are produced annu-
ally for the global market [1]. The variety of such compounds
and the percentage of different filters added to industrial prod-
ucts are expanding with the increasing demand to prevent UV
radiation-induced cell damage. Organic chemicals that absorb
UVA (400–315 nm) or UVB (315–280 nm) radiation are
added at concentrations of up to 10% to sunscreen products
for skin protection. Due to public anxiety regarding skin dam-
age caused by UV light, the use of UV screens is increasing,
even though the benefit with respect to the prevention of mel-
anoma remains controversial. In Europe, 28 chemical sub-
stances that function as UV filters are approved for use in
industry, but the European Commission has reported many
of them as hormonally active substances or endocrine-
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disrupting chemicals (EDCs). Chemical filters are almost al-
ways used in the mixtures but none of them are used individ-
ually in cosmetic in acceptable concentrations and does not
provide adequate protection. These compounds are approved
as harmless when used in small doses, but it should be noted
that daily use involves at least several different cosmetics.
Benzophenone-3 (2-hydroxy-4-methoxybenzophenone,
oxybenzone, 2OH-4 MeO-BP or BP-3) is a commonly used
sunscreen agent, absorbing UVB and UVA radiation. The in-
dustrial use of BP-3 has increased over the past decade [2].
BP-3 is utilized as a flavor ingredient; a fragrance enhancer; a
perfume fixative, an additive for plastics, coatings, and adhe-
sive formulations; an ultraviolet curing agent in sunglasses;
and as an agent to prevent UV light from damaging scents and
colors in perfumes and soaps. It can be added to plastic pack-
aging as a UV blocker, which allows manufacturers to pack-
age their products in clear glass or plastic rather than in dark
packaging. Additionally, BP-3 has been approved by the US
Food and Drug Administration as an indirect food additive
[3]. Population studies have demonstrated that it penetrates
through the skin and is excreted in the urine. BP-3 was found
in >95% of urine samples collected from the US general pop-
ulation and in 100% of an investigated group of Danish chil-
dren at concentrations ranging from 0.4 to 21,700 ng/ml
[4–8]. In some cases, as much as 10% of the applied dermal
dose was absorbed into systemic circulation [9]. BP-3 was
found in 83% of blood samples from investigated adults [10].
The majority of reports have concentrated on the negative
effects of BP-3 on the reproductive system. Epidemiological
studies have provided evidence of a strong correlation be-
tween BP-3 exposure and increased ratios of diagnosed endo-
metriosis [11]. However, the most disturbing finding is the
fact that breastfed babies are exposed to BP-3, as this UV filter
was detected in humanmilk samples [12]. In addition to moth-
er milk, other ways of exposures to BP-3 are possible. BP-3
was found to cross blood-brain barrier after being applied in
gavages [13]. It has been demonstrated that bisphenol A
(BPA), which chemical structure is very similar to BP-3, eas-
ily crosses the blood–placental barrier [14, 15]. Therefore,
fetal brain could be exposed to a much higher concentration
of BP-3 than the concentration that was detected in human
milk fat by Schlumpf et al. [12]. The high concentrations of
BP-3 that have been detected in mother’s urine may reduce
birth weight in girls and increase birth weight and head cir-
cumference in boys [6, 16]. It has been postulated that the BP-
3 concentration in urine may reach 16.7 μg/l and it may reflect
less than 1% of the concentration of BP-3 to which healthy
volunteers were exposed [17, 18]. Furthermore, a strong asso-
ciation between maternal exposure to BP-3 and the onset of
Hirschsprung’s disease in offspring has been shown [19]. In
addition to the above-mentioned studies, there is insufficient
data on the impact of BP-3 on the nervous system, including
its possible adverse effects on the developing brain. The only
relevant report showed apoptotic and neurotoxic effects of
BP-3 on SH-SY5Y neuroblastoma cells [20].
BP-3 has frequently been reported to play a role in endo-
crine disruption [21–24]. This disruption can occur by altering
normal hormone levels, inhibiting or stimulating the produc-
tion and metabolism of hormones, or changing the way hor-
mones travel through the body, thus affecting the functions
that these hormones control. EDCs have been postulated to
exert their actions through nuclear hormone receptors, includ-
ing estrogen receptors and peroxisome proliferator-activated
receptor gamma (PPARγ), either by activating or by suppress-
ing them. Although BP-3 has been recognized as a ligand for
nuclear estrogen receptors (ERs), there is no data regarding its
interactions with newly identified membrane ER, G protein-
coupled receptor 30 (GPR30), and the nuclear receptor
PPARγ, which is known to interact with ERs. Identifying
chemicals that display hormonal activity is now a major re-
search focus because they could disrupt brain development
and cause abnormalities observed during ontogeny or at the
onset of neurodegenerative diseases.
Primarily, ERs mediate the actions of endogenous estrogen
hormones, which influence a wide variety of developmental
and functional aspects in the mammalian central nervous sys-
tem (CNS). This includes the survival of neurons, the growth
and plasticity of neurites, their synaptic connections and trans-
mission, and motor skills and higher cognitive functions [25].
Experimental and epidemiologic studies have provided infor-
mation that estrogens protect against Alzheimer’s disease
(AD) in postmenopausal women and positively affect the
symptoms of Parkinson’s disease and tardive dyskinesia
[26]. The idea of a neuroprotective function of estrogen is
supported by observations that females are less vulnerable to
acute insults associated with cerebral ischemia, neurotrauma,
and hypoxia and that estradiol or estrogen-like compounds
protect against stroke [27, 28]. Surprisingly, EDCs interfer-
ence with nuclear receptors implicated in metabolism has
remained scarcely studied. Peroxisome proliferator-activated
receptors are ligand-activated transcription factors that regu-
late genes important in cell differentiation and various meta-
bolic processes, especially lipid and glucose homeostasis [29].
These receptors are important for neuronal development and
brain function. Agonists of PPARγ have been used to reduce
neurodegenerative changes in mouse models of neurodegen-
erative diseases [30] and have also shown benefits in experi-
mental models of stroke and ischemia [31]. Concomitantly,
studies of PPARγ activation showed effects against oxidative
stress, mitochondrial dysfunction, and apoptosis in several cell
models that resemble AD, Huntington’s disease (HD), amyo-
trophic lateral sclerosis (ALS), and spinal cord injuries (SCI)
[32]. A signal cross-talk between nuclear ERs and the PPARγ
has also been shown [33]. However, there is no data on the
interactions of BP-3 with these receptors in mammalian
neurons.
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Recently, we showed that the pesticide dichlorodiphenyltri-
chloroethane (DDT) impaired Gpr30-mediated intracellular sig-
naling inmouse neurons [34].We also demonstrated an involve-
ment of the retinoid X receptor (Rxr), which is an obligatory
heterodimer partner of Pparγ, in the neurotoxic and apoptotic
actions of nonylphenol and dichlorodiphenyldichloroethylene
(DDE) [35, 36]. The present study aimed to investigate the
neurotoxic and apoptotic effects of BP-3 and the impact of this
chemical on the expression and functions of ERs, including
classical Erα/Erβ, the membrane Gpr30 and Pparγ.
Neurotoxicity was estimated by measuring lactate dehydroge-
nase (LDH) release, whichwas complemented by an assessment
of caspase-3 and -8 activities and a loss of mitochondrial mem-
brane potential and ROS production. These data were supported
by Hoechst 33342/calcein acetoxymethyl (AM) staining, which
allowed for apoptotic nuclei and cell survival to be visualized,
respectively, and by measurements of the expression of genes
involved in apoptosis, as detected by a microarray analysis.
Specific inhibitors of caspase-8, caspase-9, glycogen synthase
kinase-3β (Gsk3β), and p38/MAPK were employed to indicate
which of these enzymes participated in BP-3-induced caspase-3-
dependent apoptosis. The involvement of classical and mem-
brane ERs and Pparγ in BP-3 actions was verified using selec-
tive antagonists and agonists. The levels of specific messenger
RNAs (mRNAs) and proteins were measured with quantitative
polymerase chain reaction (qPCR), western blot, and ELISA,
and the cellular distributions of receptors were demonstrated
using a confocal microscope.
Materials and Methods
Materials
B27 and neurobasal media were obtained from Gibco (Grand
Island, NY, USA). L-glutamine; fetal bovine serum (FBS); N-
acetyl-Asp-Glu-Val-Asp p-nitro-anilide (Ac-DEVD-pNA); di-
methyl sulfoxide (DMSO); HEPES; CHAPS;mousemonoclo-
nal anti-MAP-2 antibody; ammonium persulfate; TEMED;
TRIZMA base; Tween 20; DL-dithiothreitol; Nonidet NP-40;
sodium deoxycholate; protease inhibitor (EDTA-free);
bromophenol blue; 2′,7′-dichlorofluorescein diacetate;
Gsk3β; p38/MAPK; caspase-9 and caspase-8 inhibitors (SB
216763, SB 203580, Z-Leu-Glu(O-Me)-His-Asp(O-Me)
fluoromethyl ketone trifluoroacetate salt hydrate, Z-Leu-
Glu(OMe)-Thr-Asp(OMe) fluoromethyl ketone); RIPA buffer;
protease inhibitor cocktail for mammalian tissues; and poly-
ornithine were obtained from Sigma-Aldrich (St. Louis, MO,
USA). Bradford reagent, SDS, 30% acrylamide, 0.5 M Tris-
HCl buffer, 1.5 M Tris-HCl gel buffer, and Laemmli sample
buffer were from Bio-Rad Laboratories (Munchen, Germany).
4,4′,4″-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT),
2,3-bis(4-Hydroxyphenyl)-propionitrile (DPN), G1, ICI
182780, GW1929, methylpiperidino-pyrazole (MPP), 4-[2-
phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5,-a]pyrimidin-3-
yl]phenol (PHTPP), G15, and GW9662 were from Tocris
Bioscience (Minneapolis, MN, USA). 2-mercaptoethanol was
from Carl Roth GmbH+ Co. KG, (Karlsruhe, Germany).
Immobilon-P membranes were purchased from Millipore
(Bedford, MA, USA). Alexa 488-conjugated anti-goat IgG,
calcein AM, and Hoechst 33342 were purchased from
Molecular Probes (Eugene, OR, USA). Cy3-conjugated anti-
rabbit IgG andCy5-conjugated anti-mouse were obtained from
Jackson ImmunoResearch, Inc. (West Grove, PA, USA). The
cytotoxicity detection kit and BM Chemiluminescence
Western Blotting Substrate (POD) were purchased from
Roche Diagnostics GmbH (Mannheim, Germany). ELISA as-
say kits for Erα, Erβ, Gpr30 and Pparγ were purchased from
Shanghai Sunred Biological Technology Co. (Sunred, China).
The culture dishes were obtained from TPP Techno Plastic
Products AG (Trasadingen, Switzerland). Rabbit polyclonal
anti-Erα antibody (sc-7207), goat polyclonal anti-Erβ anti-
body (sc-6822), rabbit polyclonal anti-Erβ antibody (sc-
8974), rabbit polyclonal anti-Gpr30 antibody (sc-134576),
mouse monoclonal anti-Pparγ antibody (sc-7273), mouse
monoclonal anti-β-Actin antibody (sc-47778), Erα siRNA
(sc-29306), Erβ siRNA (sc-35326), Gpr30 siRNA (sc-
60744), and Pparγ siRNA (sc-29456) were purchased from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).
AllStars Negative Control siRNA AF 488, RNeasy Mini Kit
and RT2 Profiler PCR Apoptosis Array were obtained from
QIAGEN (Valencia, CA, USA). INTERFERin was obtained
from PolyPlus Transfection (Illkirch, France), and the high-
capac i ty complementary DNA (cDNA)-Reverse
Transcription Kit, the TaqMan Gene Expression Master Mix
and TaqMan probes corresponding to specific genes encoding
Hprt, Erα, Erβ, Gpr30, and Pparγ were obtained from Life
Technologies Applied Biosystems (Foster City, CA, USA).
JC-1 was obtained from Biotium, Inc. (Hayward, CA, USA).
Primary Neocortical and Hippocampal Neuronal Cell
Cultures
Neocortical and hippocampal tissues for primary cultures
were prepared from Swiss mouse embryos (Charles River,
Germany) at 15–17 days of gestation and cultured as previ-
ously described [37]. All procedures were performed in accor-
dance with the National Institutes of Health Guidelines for the
Care and Use of Laboratory Animals and approved by the
Bioethics Commission in compliance with Polish Law (21
August 1997). Animal care followed official governmental
guidelines, and all efforts were made to minimize suffering
and the number of animals used. The cells were suspended in
estrogen-free neurobasal medium with a B27 supplement on
poly-ornithine (0.01 mg/ml)-coated multi-well plates at a den-
sity of 2.0 × 105 cells/cm2. The cultures were maintained at
Mol Neurobiol
37 °C in a humidified atmosphere containing 5% CO2 for
7 days in vitro (DIV) prior to experimentation. The number
of astrocytes, as determined by the content of intermediate
filament glial fibrillary acidic protein (GFAP), did not exceed
10% for all cultures [38].
Treatment
Primary neuronal cell cultures were exposed to BP-3 (1–
100 μM) for 6 or 24 h. To assess whether the effects of BP-3
were tissue-dependent, we examined these effects in neocorti-
cal and hippocampal cultures. The involvement of ER signal-
ing in BP-3-induced effects was verified with the high-affinity
estrogen receptor antagonist ICI 182,780 (1 μM), also known
to act as a membrane estrogen receptor Gpr30 agonist [39], the
Erα antagonist methyl-piperidino-pyrazole (MPP; 1 μM), the
Erα agonist 4,4 ′,4″-(4-Propyl-[1H]-pyrazole-1,3,5-
triyl)trisphenol (PPT; 1 μM), the Erβ antagonist 4-[2-phenyl-
5,7-bis(trifluoromethyl)pyrazolo[1,5,-a]pyrimidin-3-yl]phenol
(PHTPP; 1 μM), the Erβ agonist 2,3-bis(4-Hydroxyphenyl)-
propionitrile (DPN; 1 μM), the Gpr30 antagonist G-15
(10 μM), and the Gpr30 agonist G-1 (1 μM). BP-3-induced
Pparγ activation was examined using the receptor agonist
GW1929 (1 μM) and antagonist GW9662 (1 μM). For apo-
ptotic signaling, we used a cell permeable Gsk3β inhibitor SB
216763 (3-(2,4-dichlorophenyl)-4-(1-methyl-1Hindol-3-yl)-
1H-pyrrole-2,5-dione; 1 μM) and a p38/MAPK inhibitor SB
203580 (4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-
pyridyl)-1H-imidazole; 1 μM) and caspase-8 and caspase-9
inhibitors: Z-Leu-Glu(O-Me)-Thr-Asp(O-Me)-fluoromethyl
ketone (Z-LETD-FMK; 40 μM) and Z-Leu-Glu(O-Me)-His-
Asp(O-Me)-fluoromethyl ketone trifluoroacetate salt hydrate
(Z-LEHD-FMK; 40 μM), respectively. GW1929, GW9662,
ICI 182780, MPP, PPT, DPN, and PHTPP were added to the
culture media 45–60 min before BP-3 was added. The other
agents were introduced simultaneously with BP-3. To avoid
non-specific effects in our study, specific receptor ligands and
SB 216763, SB 203580, and the caspase inhibitors were used
at concentrations that did not affect the control levels of
caspase-3 activity or LDH release. All the compounds were
originally dissolved in DMSO and then further diluted in cul-
ture medium to maintain the DMSO concentration below
0.1%. The control cultures were treated with DMSO in con-
centrations equal to those used in the experimental groups.
Identification of Apoptotic Cells
Apoptotic cells were detected via Hoechst 33342 staining at
24 h after the initial treatment, as previously described [37].
Neocortical cells cultured on glass coverslips were washed
with 10-mM phosphate-buffered saline (PBS) and exposed
to Hoechst 33342 (0.6 mg/ml) staining at room temperature
(RT) for 5 min. The cells containing bright blue fragmented
nuclei, indicating condensed chromatin, were identified as
apoptotic cells. Qualitative analysis was performed using a
fluorescence microscope (NIKON Eclipse 80i, NIKON
Instruments Inc., Melville, NY, USA) equipped with a camera
with BCAM Viewer© Basler AG software.
Staining with Calcein AM
The intracellular esterase activity in the neocortical cultures
was measured based on calcein AM staining at 24 h after the
initial treatment with BP-3 [37]. To avoid the esterase activity
present in the growth media, the cells were washed with PBS
and incubated in 2 μM calcein AM in PBS at RT for 10 min.
The cells displaying bright green cytoplasm were identified as
living cells. Fluorescence intensity was monitored at Ex/Em
494/520 nm using a fluorescence microscope (NIKON
Eclipse 80i, NIKON Instruments Inc., Melville, New York,
USA) equipped with a camera with BCAM Viewer© Basler
AG software.
Assessment of Caspase-3 Activity
Caspase-3 activity was determined according to Nicholson,
using samples treated for 6 or 24 h with BP-3 alone or in
combination with the test compounds [40]. The assessment of
caspase-3 activity was performed as previously described [38].
Cell lysates from neocortical and hippocampal cultures were
incubated at 37 °C using a colorimetric substrate preferentially
cleaved by caspase-3, called Ac-DEVD-pNA (N-acetyl-asp-
glu-val-asp-p-nitro-anilide). The levels of p-nitroanilide were
continuously monitored for 60 min using a Multimode
Microplate Reader Infinite M200PRO (Tecan, Mannedorf,
Switzerland). The data were analyzed usingMagellan software,
normalized to the absorbency of vehicle-treated cells and
expressed as a percentage of control ±SEM from three to four
independent experiments. The absorbance of blanks, acting as
no-enzyme controls, was subtracted from each value.
Measurement of Lactate Dehydrogenase Activity
To quantify cell death, lactate dehydrogenase (LDH) release
from damaged cells into the cell culture media was measured
6 or 24 h after treatment with BP-3. LDH release was mea-
sured as previously described [41]. Cell-free supernatants
from neocortical and hippocampal cultures were collected
from each well and incubated at room temperature for 30 to
60 min with the appropriate reagent mixture according to the
manufacturer’s instructions (Cytotoxicity Detection Kit) de-
pending on the reaction progress. The intensity of the red color
that formed in the assay, measured at a wavelength of 490 nm
(Infinite M200pro microplate reader, Tecan Mannedorf,
Switzerland), was proportional to both LDH activity and the
number of damaged cells. The data were analyzed using
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Magellan software, normalized to the color intensity from
vehicle-treated cells (100%) and expressed as a percentage
of the control value from three to four independent experi-
ments. The absorbance of blanks, acting as no-enzyme con-
trols, was subtracted from each value.
Assessment of Loss of the Mitochondrial Membrane
Potential
The loss of the mitochondrial membrane potential was mea-
sured using a JC-1 Assay Kit, which utilizes the cationic dye
5,5,6,6-tetrachloro-1,1,3,3-tetraethylbenzimidazolylcarbo-cy-
anine iodide. In healthy cells, this dye aggregates and stains
mitochondria bright red, whereas in apoptotic cells, the mito-
chondrial membrane potential collapses, and the dye remains
in the cytoplasm in a green fluorescent monomeric form. The
loss of mitochondrial membrane potential, a hallmark of apo-
ptosis, was assessed in neocortical cultures 24 h after treat-
ment with BP-3 (25 μM). The cells were incubated in the JC-1
solution for 25 min, and the red (550/600 nm) and green (485/
535 nm) fluorescence intensities were measured using an
Infinite M1000 microplate reader (Tecan, Austria). The data
were analyzed using Tecan i-control software, normalized to
the fluorescence intensity of vehicle-treated cells, and
expressed as the red to green fluorescence ratio ±SEM of three
to four independent experiments. The fluorescence intensity
of blanks, acting as no-enzyme controls, was subtracted from
each value.
ROS Formation
To determine the ability of BP-3 to induce ROS production in
the neocortical neurons, 5 μM H2DCFDA was applied as
previously described [42, 43]. After diffusion into the cell,
H2DCFDA is deacetylated by cellular esterases into a non-
fluorescent compound that is subsequently oxidized by ROS
into 2,7′-dichlorofluorescein (DCF). The cells were incubated
in serum- and phenol red-free neurobasal medium containing
H2DCFDA for 40 min before BP-3. After this time, the cul-
ture medium was replaced with fresh medium to remove ex-
tracellular residual DCF. The DCF fluorescence was measured
after 3–24 h of BP-3 treatment and detected using an Infinite
M1000 microplate reader (Tecan, Austria). The data were an-
alyzed using Tecan i-control software and normalized to the
fluorescence intensity in vehicle-treated cells (% of control).
The means ± SEM from eight separate samples were calculat-
ed from four independent experiments.
Silencing of Erα, Erβ, Gpr30, and Pparγ
Specific siRNAs were used to inhibit Erα, Erβ, Gpr30, and
Pparγ expression in neocortical cells. Each siRNA was ap-
plied separately for 6 h at 50 nM in antibiotic-free medium
containing the siRNA transfection reagent INTERFERin™.
After transfection, the culture media were changed, and the
cells were incubated for 12 h before starting the experiment.
Positive and negative siRNAs containing a scrambled se-
quence that did not lead to the specific degradation of any
known cellular mRNA were used as controls. The effective-
ness of mRNA silencing was verified through the measure-
ment of specific mRNAs using qPCR.
qPCR Analysis of mRNAs Specific to Genes Encoding
the Receptors Erα, Erβ, Gpr30, and Pparγ
Total RNA was extracted from neocortical cells cultured for
7 DIV (approx. 1.5 × 106 cells/sample) using an RNeasyMini
Kit (QIAGEN, Valencia, CA) according to the manufacturer’s
instructions. The quantity of RNAwas spectrophotometrically
determined at 260 nm and 260/280 nm (ND/1000 UV/Vis;
Thermo Fisher NanoDrop, USA). Two-step real-time PCR
was performed. Both the reverse transcription reaction and
quantitative polymerase chain reaction (qPCR) were run on
a CFX96Real-Time System (Bio-Rad, USA). The products of
the reverse transcription reaction were amplified using
TaqMan Gene Expression Master Mix containing TaqMan
primer probes specific to the genes encoding Hprt, Erα,
Erβ, Gpr30, and Pparγ. Amplification was performed in a
total volume of 20 μl of a mixture containing 10 μl TaqMan
Gene Expression Master Mix and 1.0 μl reverse transcription
product as the PCR template. A standard qPCR procedure was
performed: 2 min at 50 °C and 10min at 95 °C followed by 40
cycles of 15 s at 95 °C and 1 min at 60 °C. The threshold value
(Ct) for each sample was set during the exponential phase, and
the delta delta Ct method was used for data analysis. Hprt
(hypoxanthine phosphoribosyltransferase coding gene) was
used as a reference gene.
Mouse Apoptosis RT2 Profiler PCR Array
Total RNA was extracted from neocortical cells cultured for
7 DIV (approx. 1.5 × 106 cells/sample) using the RNeasyMini
Kit (QIAGEN, Valencia, CA) according to the manufacturer’s
instructions. The quantity of RNAwas spectrophotometrically
determined at 260 and 260/280 nm (ND/1000 UV/Vis;
Thermo Fisher NanoDrop, USA). A total of 1 μg mRNA
was reverse transcribed to cDNA using an RT2 First Strand
Kit (QIAGEN, Valencia, CA) and suspended in a final solu-
tion of 20 μl. Each cDNA was prepared for further use in
qPCR. To analyze the signaling pathway, the RT2 Profiler™
PCR Array System (QIAGEN, Valencia, CA) was used ac-
cording to the manufacturer’s protocol. The Ct values for all
wells were exported to a blank Excel spreadsheet and were




The cells exposed for 24 h to BP-3 were lysed in ice-cold
RIPA lysis buffer containing a protease inhibitor cocktail.
The lysates were sonicated and centrifuged at 15,000×g for
20 min at 4 °C. The protein concentrations in the supernatants
were determined using Bradford reagent (Bio-Rad Protein
Assay) with bovine serum albumin (BSA) as the standard.
Samples containing 40 μg of total protein were reconstituted
in the appropriate amount of sample buffer comprising
125 mM Tris, pH 6.8, 4% SDS, 25% glycerol, 4 mM
EDTA, 20mMDTT, and 0.01% bromophenol blue, denatured
and separated on 7.5% SDS-polyacrylamide gel using a Bio-
Rad Mini-Protean II Electrophoresis Cell, as previously de-
scribed [44]. After electrophoretic separation, the proteins
were electrotransferred to PVDF membranes (Millipore,
Bedford, MA, USA) using the Bio-Rad Mini Trans-Blot ap-
paratus. Following the transfer, the membranes were washed,
and non-specific binding sites were blocked with 5% dried
milk and 0.2% Tween-20 in 0.02 M Tris-buffered saline
(TBS) for 2 h while shaking. The membranes were incubated
overnight (at 4 °C) with one of the following primary antibod-
ies (Santa Cruz Biotechnology): anti-Erα rabbit polyclonal
antibody (diluted 1:200), anti-Erβ rabbit polyclonal antibody
(diluted 1:200), anti-Gpr30 rabbit polyclonal antibody (dilut-
ed 1:150), anti-Pparγ mouse polyclonal antibody (diluted
1:150) or anti-β-actin mouse monoclonal antibody (diluted
1:3000) diluted in TBS/Tween. The signals were developed
by chemiluminescence (ECL) using BM Chemiluminescence
Blotting Substrate (Roche Diagnostics GmBH) and visualized
using a Luminescent Image Analyzer Fuji-Las 4000 (Fuji,
Japan). Immunoreactive bands were quantified using a
MultiGauge V3.0 image analyzer.
Enzyme-Linked Immunosorbent Assays for Erα, Erβ,
Gpr30, and Pparγ
The levels of Erα, Erβ, Gpr30, and Pparγ were determined in
neocortical cells 24 h after treatment with BP-3. Specific detec-
tion of these proteins was obtained using enzyme-linked immu-
nosorbent assays (ELISAs) and the quantitative sandwich en-
zyme immunoassay technique. A 96-well plate was pre-coated
with monoclonal antibodies specific to Erα, Erβ, Gpr30, or
Pparγ. The standards and non-denatured cell extracts were
added to the wells with biotin-conjugated polyclonal antibodies
specific for Erα, Erβ, Gpr30, or Pparγ. Therefore, all native
Erα, Erβ, Gpr30, or Pparγ proteins were captured using the
immobilized antibodies. The plates were washed to remove any
unbound substances, and horseradish peroxidase-conjugated
avidin was added to interact with the biotin bound to Erα,
Erβ, Gpr30, or Pparγ. After washing, the substrate solution
was added to the wells. The enzyme reaction yielded a blue
product. The absorbance was measured at 450 nm and was
proportional to the amount of Erα, Erβ, Gpr30, or Pparγ.
The protein concentration was determined in each sample using
Bradford reagent (Bio-Rad Protein Assay).
Immunofluorescent Labeling of Erα, Erβ, Gpr30,
and Pparγ and Confocal Microscopy
For immunofluorescence detection of Erα, Erβ, Gpr30, and
Pparγ, neocortical cells were grown on glass coverslips and
subjected to immunofluorescence double-labeling, as previ-
ously described [45]. After 1 h of incubation in a blocking
buffer (5% normal donkey serum and 0.3% Triton X-100 in
0.01 M PBS), the cells were treated for 24 h (at 4 °C) using
five primary antibodies: rabbit polyclonal anti-Erα antibody
(1:50), goat polyclonal anti-Erβ antibody (1:50), rabbit poly-
clonal anti-Gpr30 antibody (1:50), mouse monoclonal anti-
Pparγ antibody (1:50), and anti-MAP2 mouse monoclonal
(1:100), followed by a 24-h incubation in a mixture of sec-
ondary antibodies, including Alexa Fluor 488-conjugated an-
ti-rabbit IgG (1:300), Cy3-conjugated anti-rabbit IgG (1:300),
and Cy5-conjugated anti-mouse IgG (1:300). The samples
were subsequently washed, mounted, coverslipped and ana-
lyzed using an LSM510 META, Axiovert 200 M confocal
laser scanning microscope (Carl Zeiss MicroImaging
GmbH, Jena, Germany) under a Plan-Neofluar 40×/1.3 Oil
DIC objective. An He/Ne laser and an argon laser, with two
laser lines emitting at 488, 514, and 633 nm, were used to
excite the Alexa Fluor 488-, Cy3- and Cy5-conjugated anti-
bodies, respectively. The fluorescence signal was enhanced
after summing four scans per line. A pinhole value of 1 airy
unit was used to obtain flat images.
Data Analysis
Statistical tests were performed on raw data expressed as the
mean arbitrary absorbance or fluorescence units per well con-
taining 50,000 cells (measurements of caspase-3, LDH), the
fluorescence units per 1.5 million cells (qPCR), the mean op-
tical density per 40 μg of protein (Western blotting) or pico-
gram of Erα, Erβ, Gpr30, and Pparγ per microgram of total
protein (ELISAs). One-way analysis of variance (ANOVA)
was preceded by the Levene test of homogeneity of variances
and used to determine overall significance. Differences be-
tween control and experimental groups were assessed using
a post hoc Newman–Keuls test, and significant differences
were designated as *p < 0.05, **p < 0.01, ***p < 0.001 (ver-
sus control cultures), #p < 0.05, ##p < 0.01, and ###p < 0.001
(versus the cultures exposed to BP-3) and $p < 0.05 and
$$$p < 0.001 (versus the siRNA-transfected control cultures).
The results were expressed as the mean ± SEM of three to four
independent experiments. The number of replicates in each
experiment ranged from 2 to 3, except for measurements of
caspase-3 activity and LDH release, with replicates ranging
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from 5 to 8. To compare the effects of BP-3 in various brain
tissues and different treatment paradigms, the results corre-
sponding to caspase-3, LDH, and western blot analysis were
presented as a percentage of the control.
Results
Effects of BP-3 on Caspase-3 and Caspase-8 Activities
and LDHRelease andMitochondrialMembrane Potential
in 7 DIV Neocortical Cultures
In 7 DIV neocortical cultures, BP-3 (25–100 μM)-induced
caspase-3 increased to 160% of the control level at 6 h and
was further enhanced to 190% at 24 h post-treatment (Fig. 1a).
In these cells, LDH release values increased in neocortical cells
in a time-dependent manner to 150–180% of the control value
at 6 h and to 210–280% at 24 h (Fig. 1b). BP-3 at concentra-
tions of 1–50 μMwas not effective at activating caspase-8, but
BP-3 at concentrations of 75–100 μM increased enzyme activ-
ity to 125–150% of the control value. (Fig. 1c). In 7 DIV
cultures, treatment with 25 μM BP-3 decreased the mitochon-
drial membrane potential by 31% (Fig. 1d).
Effects of BP-3 on Caspase-3 Activity and LDH Release
in 7 DIV Hippocampal Cultures
In hippocampal cultures exposed to 1–100 μM BP-3, the ac-
tivity of caspase-3 increased to 150% at 6 h and to 160% at
24 h (Fig. 2a). LDH release increased with the duration of BP-
3 treatment and was elevated to 150 and 208% of the vehicle
control at 6 and 24 h, respectively (Fig. 2b). BP-3-induced
caspase-3 activity and LDH release in hippocampal cells were
lower than those in neocortical cells.
Effects of BP-3 on Caspase-3 Activity and LDH Release
in 2 and 12 DIV Primary Cultures of Mouse Neocortical
Cells
To assess whether the effects of BP-3 depended on the age of
the neuronal tissue, we studied them in 2 and 12 DIV neocor-
tical cultures. In 2 DIV cultures, 25 μM BP-3 activated
caspase-3 to 120% of the control value (Fig. 3a). BP-3-
induced LDH release was enhanced to 131–138% of the con-
trol level at 6 h, after which it decreased to 119–126% at 24 h
(Fig. 3b).
In 12 DIV cultures treated with 25–50 μMBP-3, the activ-
ity of caspase-3 rose to 131 and 148% of the control level at 6
and 24 h, respectively (Fig. 3c). In these cells, the LDH release
was elevated to 121–145% of the control value (Fig. 3d). The
effects of BP-3 in 2 and 12 DIV neocortical cultures were
lower compared to the effects in 7 DIV neocortical cultures.
Effects of BP-3 on ROS Production in 7 DIV Primary
Cultures of Mouse Neocortical Cells
Following exposure to 25 μM BP-3, ROS production in-
creased in the neurons in a time-dependent manner.
Compared with the controls, ROS production reached values
of 153% at 3 h, 196% at 6 h, and 214% at 24 h (Fig. 4).
Impact of the Caspase-9, Caspase-8, Gsk3β,
and p38/MAPK Inhibitors on BP-3-Induced Caspase-3
Activity and LDH Release
In the presence of the caspase-9 inhibitor Z-LEHD-FMK
(40 μM), the activity of caspase-3 was diminished by 78%
at 24 h of exposure (Fig. 5a). A 24-h treatment with Gsk3β
inhibitor SB 216763 (1 μM) and p38/MAPK inhibitor SB
203580 (1 μM) decreased BP-3-stimulated caspase-3 activity
by 55 and 31%, respectively (Fig. 5a). However, exposure to
the caspase-8 inhibitor Z-LETD-FMK (40 μM) did not sig-
nificantly affect the BP-3-activated caspase-3 in mouse neo-
cortical cells at 7 DIV.
In neocortical cultures, caspase-9, Gsk3β, and p38/
MAPK inhibitors decreased BP-3-stimulated LDH release
by 67, 57, and 46%, respectively (Fig. 5b). Co-treatment with
caspase-8 inhibitor Z-LETD-FMK (40 μM) did not signifi-
cantly influence the BP-3-induced effect in 7 DIV neocortical
cultures.
Effects of BP-3 on the Expression Profiles of Genes
Involved in Apoptosis Using a Mouse Apoptosis RT2
Profiler PCR Array.
To validate that BP-3 induced apoptosis in neuronal cells, we
analyzed a total number of 84 key genes involved in pro-
grammed cell death. Among them, 46 genes were differentially
expressed in response to BP-3: 45 were upregulated (red color)
and 1 was downregulated (green color) in the BP-3-treated sam-
ples. The upregulated genes were Anxa5, Apaf1, Api5, Atf5,
Bad, Bag1, Bag3, Bcl10, Bcl2l11, Birc2, Birc3, Birc5, Bnip2,
Bnip3, Bnip3l, Card10, Casp1, Casp2, Casp3, Casp4, Casp9,
Cflar, Dad1, Dffa, Dffb, Diablo, Fadd, Fas, Fasl, Gadd45a,
Igf1r, Ltbr, Mapk1, Mcl1, Naip2, Nfkb1, Polb, Prdx2, Ripk1,
Tnfrsf10b, Tnfsf12, Traf2, Traf3, Trp53bp2, Trp73, and Xiap.
The only downregulated gene was Card10 (Fig. 6).
Effect of BP-3 on mRNA Levels of Erα, Erβ, Gpr30,
and Pparγ
Treatment with BP-3 (25 μM) evoked changes in the mRNA
levels of Erα, Erβ, Gpr30, and Pparγ. A 3-h exposure of the
neocortical cultures to BP-3 caused a 45% decrease in Erα, a
23% decrease inErβ, and a 60% decrease inGpr30 but caused
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(Fig. 7a). The pattern of mRNA expression was changed after
prolonged exposure to BP-3, especially with respect to Erβ
and Pparγ. At 6 and 24 h of the experiment, BP-3 stimulated
the mRNA expression of Erβ (39–58%) but inhibited the ex-
pression of Pparγ (32–39%) in neocortical cells (Fig. 7b, c).
These data were normalized to Hprt as a control.
Effects of BP-3 on the Protein Expression Levels of Erα,
Erβ, Gpr30, and Pparγ in Mouse Neocortical Cells
A 24-h exposure to BP-3 was necessary to detect changes in the
protein levels of the receptors. In the control cultures, Erα and
Pparγ reached 2.90 and 9.51 pg per microgram of total protein,
respectively. A 24-h exposure to BP-3 (25 μM) decreased Erα
and Pparγ levels by 21–27% of the control values (Fig. 8a, b).
In cultures exposed to BP-3 (25 μM) for 24 h, the concen-
tration of Erβ was 0.83 pg per micrograms of total protein,
and it was 45% larger than in control cultures (Fig. 8a, b). In
the cultures exposed to BP-3, the level of Gpr30 reached
0.05 pg and it was reduced by 32% compared to the control.
The western blot analysis demonstrated the constitutive
protein expression of Erα, Erβ, Gpr30, and Pparγ in mouse
neocortical cells at 7 DIV (Fig. 8c). Exposure to BP-3
(25 μM) decreased the relative Erα, Gpr30, and Pparγ protein
levels by 28, 19, and 64%, respectively, at 24 h post-treatment.
Treatment with BP-3 (25 μM) increased the relative Erβ pro-
tein level by 66% (Fig. 8c, d).
Effects of BP-3 Alone or in Combination with Receptor
Agonists/Antagonists on BP-3-Induced Caspase-3 Activity
and LDH Release in Neocortical Cultures
A 24-h exposure of neocortical cultures to BP-3 (25 μM)
caused almost a 50% increase in caspase-3 activity in the
neuronal cells. Co-treatment with the selective Erβ and
Gpr30 agonists, DPN (1 μM) and G1 (10 μM), enhanced
the action of BP-3 on caspase-3 activity by 21 and 56%, re-
spectively. The selective Erα agonist PPT and Pparγ agonist
GW 1929 (both 1 μM) significantly diminished the effect of
25 μM BP-3 in the mouse neuronal cell cultures (Fig. 9a).
The selective Erα agonist PPT (1 μM) and Pparγ agonist



























































Fig. 2 Time-course effects of
BP-3 (1, 10, 25, 50, 75, and
100 μM) on caspase-3 activity (a)
and LDH release (b) in primary
cultures of mouse hippocampal
cells at 7 DIV. The cells were
treated with BP-3 for 6 and 24 h.
The results are presented as a
percentage of the control. Each
bar represents the mean of three
to four independent experiments
± SEM. The number of replicates
in each experiment ranged from 5
to 8. *p < 0.05, **p < 0.01, and
***p < 0.001 versus control
cultures
Fig. 1 Time-course effects of BP-3 (1, 10, 25, 50, 75, and 100 μM) on
caspase-3 activity (a), LDH release (b), caspase-8 activity (c), and
mitochondrial membrane potential (d) in primary cultures of mouse
neocortical cells at 7 DIV. The cells were treated with BP-3 for 6 and
24 h. The results are presented as a percentage of the control. Each bar
represents the mean of three to four independent experiments ± SEM. The
number of replicates in each experiment ranged from 5 to 8. *p < 0.05,
**p < 0.01, and ***p < 0.001 versus control cultures
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release. In addition, high-affinity estrogen receptor antagonist
ICI 182780 (1 μM) and selective Erβ or Gpr30 agonists in-
tensified BP-3-induced LDH release (Fig. 9b).
The Erβ antagonist PHTPP (1 μM) and the Gpr30 antag-
onist G15 (10 μM) inhibited the BP-3 (25 μM)-induced























































































































Fig. 3 Time-course effects of
BP-3 (10, 25, 50 μM) on caspase-
3 activity (a, c) and LDH release
(b, d) in primary cultures of
mouse neocortical cells at 2 and
12 DIV. The cells were treated
with BP-3 for 6 and 24 h. The
results are presented as a
percentage of the control. Each
bar represents the mean of three
to four independent experiments
± SEM. The number of replicates
in each experiment ranged from 5
to 8. *p < 0.05, **p < 0.01, and































































Fig. 5 Impact of the caspase-9, caspase-8, Gsk3β, and p38/MAPK
inhibitors on BP-3-induced caspase-3 activity and LDH release in
7 DIV neocortical cultures. Primary neocortical cultures were treated
with BP-3 (25 μM) for 24 h. The caspase-9 inhibitor Z-LEHD-FMK
(40 μM), caspase-8 inhibitor Z-LETD-FMK (40 μM), Gsk3β inhibitor
SB 216763 (1 μM) and p38/MAPK inhibitor SB 203580 (1 μM) were
added into the culture media simultaneously with BP-3. The results were
normalized to the absorbency in vehicle-treated cells and expressed as a
percentage of the control. Each bar represents the mean of three to four
independent experiments ± SEM. The number of replicates in each ex-
periment ranged from 5 to 8. ***p < 0.001 versus control cultures;




























Fig. 4 The effect of 25 μMBP-3
on ROS production after 3, 6, and
24 h. The data are expressed as
the means ± SEM of four inde-
pendent experiments, each of
which consisted of eight repli-
cates per treatment group.
***p < 0.001 versus the control
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selective Erα antagonist MPP (1 μM) and the Pparγ antago-
nist GW 9662 did not change this effect. Treatment of the
neocortical cultures with the high-affinity estrogen receptor
antagonist ICI 182780 (1 μM), which was recently found to
possess properties of a Gpr30 agonist, potentiated the BP-3-
stimulated caspase-3 activity by 40% (Fig. 9c).
As demonstrated in Fig. 9d, 1 μM PHTPP or G15 reduced
LDH release by 48 and 53% in the cultures subjected to BP-3
(25 μM) for 24 h. In this study, exposure to MPP or GW 9662
did not affect BP-3-induced LDH release in the mouse neo-
cortical cultures. In addition, the high-affinity estrogen recep-
tor antagonist ICI 182780 (1 μM) intensified BP-3-induced
LDH release (Fig. 9d).
Effects of BP-3 Alone or in Combination with MPP,
PHTPP, G15, andGW9662 onHoechst 33342 andCalcein
AM Staining in Neocortical Cultures
In the present study, a 24-h exposure to BP-3 was necessary to
develop an apoptotic morphology of cell nuclei. A continuous
24-h exposure of neocortical cultures to BP-3 (25 μM) in-
duced apoptosis in mouse neuronal cells, as evidenced by
Hoechst 33342 staining. The formation of bright blue
fragmented nuclei containing condensed chromatin was la-
beled with Hoechst 33342 (Fig. 10). Treatment with BP-3
reduced the density of calcein AM-stained living cells at
7 DIV, as indicated by the decreased number of cells
Fig. 6 Gene expression patterns
of apoptosis in the control and
BP-3 groups showing the 46
genes that were differentially
expressed with statistical
significance between control and
BP-3 group. Among these genes,
45 genes were upregulated (red
color), and 1 gene was
downregulated (green panel) in
the BP-3-treated samples
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exhibiting light-colored cytoplasm. Co-treatment with MPP
(1 μM) and GW 9662 (1 μM) did not significantly affect
Hoechst 33342 and calcein AM staining. However, the addi-
tion of PHTPP (1 μM) and G15 (10 μM) inhibited the BP-3-
induced effects.
Influence of BP-3 on Caspase-3 Activity and LDHRelease
in Neocortical Cells Transfected with Erα, Erβ, Gpr30,
and Pparγ siRNAs
A 24-h exposure to BP-3 (25 μM) only slightly enhanced
caspase-3 activity and LDH release in the Erβ and Gpr30
siRNA-transfected cells, suggesting that the transfected cells
were less vulnerable to BP-3 than the non-transfected cells. In
comparison to non-transfected cells, in the siRNA-transfected
cells, the effects of BP-3 were reduced by 55% with respect to
caspase-3 and by 65% with respect to LDH (Fig. 11a, b).
A 24-h exposure of Erα and Pparγ siRNA-transfected cells
to 25 μM BP-3 increased caspase-3 activity and LDH release
by 85 and 75% over the control, respectively (Fig. 11a, b).
These cells were vulnerable to BP-3 in the same way as the
non-siRNA-treated wild cells.
The effectiveness of mRNA silencing was verified by mea-
suring the specific mRNAs using qPCR. In this study, mRNA
silencing decreased the Erα mRNA concentration by 62%


























































































Fig. 7 Effect of BP-3 (25μM) on
the mRNA expression levels of
Erα, Erβ, Gpr30, and Pparγ in
neocortical cultures at 7 DIV. The
extraction of total RNA at 3, 6,
and 24 h post-treatment from the
neocortical cells was followed by
reverse transcription and
quantitative polymerase chain
reaction (qPCR). The products of
the reverse transcription reaction
were amplified using TaqMan
probes and primers corresponding
to the specific genes. Hprt was
used as a reference gene. Each bar
represents the mean ± SEM of
three independent experiments.
The number of replicates for each
experiment ranged from 2 to 3,
**p < 0.01, and ***p < 0.001
versus control cultures
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(equal to 0.32-fold), the Gpr30 mRNA concentration by 59%
(equal to 0.41-fold), and the Pparγ mRNA concentration by
69% (equal to 0.31-fold) compared to the non-transfected
wild-type cells.
Effect of BP-3 on the Distribution of Erα, Erβ, Gpr30,
Pparγ, and MAP2 Staining in Neocortical Cells.
Immunofluorescence labeling and confocal microscopy re-
vealed that Erα, Erβ, Gpr30, and Pparγ were localized to











pg/µg protein Erα Erβ Gpr30 Pparγ
control 2.90379 0.57236 0.05555 9.5149









































aFig. 8 Effects of BP-3 on the
protein levels of Erα, Erβ, Gpr30,
and Pparγ in mouse neocortical
cultures at 7 DIV. The neocortical
cells were cultured for 7 DIV and
then treated for 24 h with BP-3
(25 μM). The concentrations of
the receptors were measured
using specific ELISAs and are
presented as a percentage of the
control (a) and as pg of Erα, Erβ,
Gpr30, and Pparγ per microgram
of total protein (b). For the
western blot analyses protein
samples were denatured,
electrophoretically separated,
transferred to PVDF membranes,
and subjected to immunolabeling
(c). The signals were developed
by chemiluminescence (ECL) and
visualized using a Luminescent
Image Analyzer Fuji-Las 4000
(Fuji, Japan). Immunoreactive
bands were quantified using an
image analyzer (ScienceLab,
MultiGauge V3.0), and the
relative protein levels of Erα,
Erβ, Gpr30, and Pparγ were
presented as a percentage of the
control (d). Each bar or value
represents the mean of three
independent experiments ± SEM.
The number of replicates in each
experiment ranged from 2 to 3.
**p < 0.01, and ***p < 0.001
versus control cultures
Fig. 9 Impact of Erα, Erβ, Gpr30, and Pparγ agonists and antagonists
on BP-3-induced caspase-3 activity (a, c) and LDH release (b, d) in
7 DIV neocortical cultures. The primary neocortical cultures were
treated with BP-3 (25 μM) for 24 h. The Erα, Erβ, and Pparγ agonists
(PPT, DPN, GW 1929) and antagonists (MPP, PHTPP, ICI 182780,
GW9662; 1 μM) were added to the culture media approximately 45–
60 min before BP-3 was added. The membrane ER agonist G1 (1 μM)
and antagonist G15 (10 μM) were added to the culture media
simultaneously with BP-3. The results were normalized to the
absorbency in vehicle-treated cells and are expressed as a percentage of
control. Each bar represents the mean of three to four independent
experiments ± SEM. The number of replicates in each experiment
ranged from 5 to 8. **p < 0.01, ***p < 0.001 versus control cultures,






































































































































(25 μM) increased Erβ staining but reduced Erα-, Gpr30,
and Pparγ-specific immunofluorescence. MAP2 staining
confirmed the neural localization of receptors and revealed
the BP-3-induced inhibition of neurite outgrowth
(Fig. 12).
Discussion
The primary aim of the present study was to evaluate the
apoptotic and neurotoxic effects of BP-3 on neuronal cells
with a particular emphasis on the molecular mechanisms of
its actions, including estrogen receptors and Pparγ. We dem-
onstrated that BP-3 evoked concentration-dependent activa-
tion of caspase-3 and LDH release in neocortical and hippo-
campal tissues. In the paradigms examined in the present
study, neocortical tissue responded to 25–100 μM BP-3,
whereas hippocampal cells exhibited weaker vulnerability.
The extended vulnerability of neocortical cells to BP-3 could
be due to low expression of ERs in this tissue which limits ER-
related neuroprotection [46]. Indeed, in comparison to the
hippocampal cells [42], in neocortical cells Erα protein is
present in much lower concentration as evidenced in the pres-
ent study. Recently, it has been observed that BP-3 used in
similar concentrations (0.1–100 μM) caused toxic effects in
neuroblastoma cells [20]. The BP-3 concentrations used in our
study are environmentally relevant because BP-3 has been
found in human adipose tissue at concentrations up to nearly
5 mg/kg, which is equal to approximately 22 μM [47]. In the
cited article of Wang et al. [47], provided data on accumula-
tion of BP-3 in adipose tissue were related to the concentra-
tions of the compound in males and females of Caucasian and
African-American origins and expressed as mean values.
However, the authors underlined approximately threefold
lower levels of accumulated BP-3 in African-Americans both
males and females. Therefore, the actual levels of accumulated
BP-3 in Caucasians could be much higher than the values of
30.3 and 62.2 ng/g. BP-3 is able to cross blood–brain barrier
since it has altered Erα and Erβ mRNA expression levels in
rat pituitary gland after being applied in gavages [13].
Moreover, BP-4 which is BP-3 analogue when added to water,
displayed multiple effects on gene expression in the zebrafish
brain [48].
In the present study, the biochemical alterations were ac-
companied by increased apoptotic body formation and im-
paired cell survival, evidenced by Hoechst 33342 and calcein
AM staining and by the upregulation of genes involved in
apoptosis detected by microarray analysis. The BP-3-
induced effects were age-dependent with themost pronounced
enzyme activities observed at 7, but not at 2 and 12 DIV.
Based on our results, BP-3 induced ROS formation, suggest-
ing that ROS initiated the intrinsic apoptotic pathway in neu-
ronal cells. Indeed, we indicated that BP-3 caused a substan-
tial loss of mitochondrial membrane potential, and inhibitors
of intrinsic-related caspase-9 and kinase Gsk3β reduced the
effects induced by BP-3. The cytotoxic effects of BP-3, which
involved activation of caspase-3, LDH release, decreased mi-
tochondrial membrane potential, and ROS formation, were
previously observed in the HaCaT cell line [49]. Moreover, a
reduction of ROS scavengers, i.e., GSH, in response to BP-3
control
25 μM BP-3









Fig. 10 Influence of BP-3 (25 μM) and MPP (1 μM), PHTPP (1 μM),
G15 (10 μM), GW 9662 (1 μM) on Hoechst 33,342 (first column) and
calcein AM (second column) staining in mouse neocortical cultures at
7 DIV, examined 24 h post-treatment. The Erα, Erβ, and Pparγ
antagonists (MPP, PHTPP, GW9662) were added to the culture media
approximately 45–60 min before BP-3 was added. The membrane ER
antagonist G15 (10 μM) was added to the culture media simultaneously
with BP-3. The cells were cultured on glass coverslips, washed with
10 mM PBS, and exposed to Hoechst 33342 (0.6 μg/ml) at RT for
5 min. The cells were subsequently rewashed and incubated with 2 μM
calcein AM at RT for 10 min. Cells with bright fragmented nuclei
showing condensed chromatin were identified as undergoing apoptosis,
whereas cells with light-colored cytoplasm were identified as living cells
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was observed in Tetrahymena thermophila [50]. In our study,
the apoptotic effects of BP-3 were inhibited by an inhibitor of
p38/MAPK but not by an inhibitor of extrinsic-related cas-
pase-8, thus confirming the prevalence of an intrinsic pathway
in BP-3-induced apoptosis in neural cells. Furthermore, BP-3
only partially engaged extrinsic-related caspase-8 in neuronal
apoptosis when used in higher concentrations. We postulate
that BP-3 by stimulating p38/MAPK may inhibit Er an d
Pparγ functions in neuronal cells.
Until now, UV filters, including BP-3, have been
shown to have endocrine-disrupting capacities and act
via sex steroid receptors, i.e., classical estrogen and an-
drogen receptors. However, there is no data regarding the
mechanisms of action of BP-3 in the mammalian nervous
system that involve classical and newly recognized mem-
brane estrogen receptors and Pparγ. Classical estrogen
receptors (Erα, Erβ) and Pparγ are nuclear receptors act-
ing as ligand-activated transcription factors. The estrogen
receptors when located on the plasma membranes may
rapidly activate intracellular pathways such as ERK 1/2
and PI3K kinases [51, 52]. As for Pparγ, there are no
reports on membrane localization of the receptor. In the
present study, BP-3 altered the mRNA expression levels
of Erα, Erβ, Gpr30, and Pparγ in a time-dependent man-
ner. We demonstrated that 3–24-h exposures caused
decreases in Erα and Gpr30 mRNAs. Moreover, 6–24-h
exposures to BP-3 caused a significant increase in Erβ
mRNA but decreased Pparγ mRNA. Recently, BP-3 was
found to have a direct impact on the ER-related insect
endocrine pathway, activating the ecdysone receptor gene
EcR [53]. BP-3 also transcriptionally activated human
ERα and ERβ in transfected human embryonic kidney
cells HEK293 [54]. Furthermore, BP-3 was found to
cause a strong activation of hERβ in reporter gene assays
in HELN cells [55], which is similar to the substantial
upregulation of Erβ mRNA observed in our study. We
showed that BP-3-induced patterns of mRNA expression
detected at 6 and 24 h reflected alterations in the protein
levels of the receptors, as indicated by the use of specific
ELISAs and western blot analyses. These profiles were
also in parallel with the immunofluorescent labeling of
Erα, Erβ, Gpr30, and Pparγ in response to BP-3.
Basing on these data, we hypothesize that the BP-3-
evoked apoptosis of neuronal cells is mediated via the
attenuation of Erα/Gpr30/Pparγ and the stimulation of
Erβ signaling pathways, though we did not differentiate
the effects between nuclear and membrane receptors.
The proposed hypothesis has been partially confirmed by
the use of selective receptor ligands and specific siRNAs.





























































Fig. 11 Effect of BP-3 (25 μM) on caspase-3 activity (a) and LDH
release (b) in Erα, Erβ, Gpr30, and Pparγ siRNA-transfected
neocortical cells. The primary neocortical cultures were transfected with
50 nM Erα, Erβ, Gpr30, and Pparγ siRNAs in INTERFERin™-
containing medium without antibiotics for 6 h. The results were
normalized to the absorbance in vehicle-treated cells and are expressed
as a percentage of the control, either in siRNA-transfected or non-
transfected cells. Each bar represents the mean ± SEM of three to four
independent experiments. The number of replicates in each experiment
ranged from 5 to 8. ***p < 0.001 versus the non-transfected control
cultures, $p < 0.05, $$$p < 0.001 versus the siRNA-transfected control
cultures
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but Erβ and Gpr30 agonists stimulated the BP-3-induced ap-
optotic and neurotoxic effects. In comparison to receptor ag-
onists, receptor antagonists caused opposite effects, except for
ICI 182,780, which is known to act not only as an Erα/Erβ
antagonist but also as a Gpr30 agonist. These results were
complemented by double Hoechst/calcein AM staining,
according to which the receptor antagonists PHTPP and G15
improved viability and attenuated BP-3-induced apoptosis,
whereas MPP and GW9662 did not change these parameters.
This is in line with a substantial reduction of the effects of BP-
3 in the cells with siRNA-silenced Erβ/Gpr30 and the main-












Erα Erβ Erα+ Erβ bright field
Fig. 12 Influence of BP-3 on the cellular distributions of Erα (red), Erβ
(blue), Gpr30 (red), Pparγ (blue), and MAP2 (red) in mouse neocortical
cultures at 7 DIV. The overlay of Erα/Erβ, Erβ/Gpr30, Erα/Pparγ, Erβ/
Map2, and Pparγ/MAP2 (red plus blue) and the bright field images are
also shown. The primary neocortical cultures were treated with BP-3
(25 μM) for 24 h. The cells were cultured on glass coverslips and
subjected to immunofluorescent double-labeling. The samples were
analyzed using an LSM510 META Axiovert 200 M confocal laser
scanning spectral microscope (Carl Zeiss MicroImaging GmbH, Jena,
Germany) with a Plan-Apochromat 63×/1.4 Oil DIC objective
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transfected cells. Therefore, we suggest that BP-3-evoked ap-
optosis of neuronal cells is mediated via an attenuation of Erα/
Pparγ and stimulation of Erβ/Gpr30 signaling. Recently, it
has been shown that activation of Pparγ inhibited caspase-3
activity and protected murine cortical neurons against ische-
mia [56, 57]. Reduced expression of Pparγ accompanied neu-
rotoxicity of TBBPA [58] which is in line with the effect of
BP-3 in our study. We hypothesize that the BP-3-evoked
downregulation of Pparγ is at least partially due to the upreg-
ulation of Erβ. A negative cross-talk between Erβ and Pparγ
has previously been shown in adipose tissue of βERKO mice
[59]. It is also possible that the reduced expression of Erα
observed in our study was linked to the cross-talk of Pparγ
with its heterodimeric partner, the nuclear receptor Rxrα,
through the mechanism previously detected in the vitellogenin
A2 promoter [60]. We demonstrated that the BP-3-affected
mRNA and protein expression levels of Erα, Erβ, and
Pparγ measured by qPCR, ELISAs, western blot, and immu-
nofluorescent labeling of neuronal cells are parallel to BP-3-
induced apoptosis and neurotoxicity. Although BP-3 reduced
Gpr30 mRNA and protein expression, it accelerated the func-
tion of Gpr30 in neuronal cells, thus pointing to the involve-
ment of Gpr30 in BP-3 neurotoxicity.
Conclusions
In summary, our study demonstrated that BP-3 caused neuro-
toxicity and activated apoptosis via an intrinsic pathway in-
volving the loss of mitochondrial membrane potential and the
activation of caspases-9 and -3 and kinases p38/MAPK and
Gsk3β. We showed for the first time that BP-3-evoked apo-
ptosis of neuronal cells is mediated via the attenuation of Erα/
Pparγ and the stimulation of Erβ/Gpr30 signaling, as demon-
strated using selective ligands and specific siRNAs and by
measurements of mRNA and protein expression (qPCR,
ELISA, western blot, immunofluorescent labeling) of the
receptors.
AD, Alzheimer’s disease; ALS, amyotrophic lateral sclero-
sis; AM, acetoxymethyl; ANOVA, analysis of variance; BP-3,
benzophenone-3; BSA, bovine serum albumin; CNS, central
nervous system; DDE, dichlorodiphenyldichloroethylene;
DDT, dichlorodiphenyltrichloroethane; DIV, days in vitro;
DMSO, dimethyl sulfoxide; EDCs, endocrine-disrupting
chemicals; ELISA, enzyme-linked immunosorbent assay;
ERs, estrogen receptors; FBS, fetal bovine serum; GFAP, glial
fibrillary acidic protein; Gpr30, G protein-coupled receptor
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phosphoribosyltransferase; LDH, lactate dehydrogenase;
mRNA, messenger RNA; PBS, phosphate-buffered saline;
Ppar, peroxisome proliferator-activated receptors; qPCR,
quantitative polymerase chain reaction; ROS, reactive oxygen
species; RT, room temperature; Rxr, retinoid X receptor; SCI,
spinal cord injuries; SEM, standard error of the mean; TBS,
tris-buffered saline; UV, ultra violet light
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